Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment

Wang, Yu; Wang, Qianmei; Feng, Wei; Qian, Yuan; Qi, Xiaowei; Chen, Sheng; Pu, Yulin; Dai, Qing; Xia, Peiyuan; Zhang, Dinglin; Sun, Fengjun

doi:10.1080/10717544.2021.1963351

Cited by 26 publications

(18 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors also evaluated the NPs’ efficacy in vivo and found that FA modification enhanced the anti-tumor activity of Luteolin-loaded NPs. These results were in accordance with the in vitro anti-tumor efficacy results [ 55 ]. In another study, Sriraman et al evaluated different liposomal formulations for their targeting ability and anti-tumor efficacy in vitro, spheroids, and in vivo.…”

Section: Resultssupporting

confidence: 92%

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

2023

View full text Add to dashboard Cite

The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production. In this study, folic acid (FA) was conjugated with a PLGA polymer followed by the formulation of drug-loaded NPs. The results of the conjugation efficiency confirmed the conjugation of FA with PLGA. The developed folic acid-conjugated nanoparticles demonstrated uniform particle size distributions and had visible spherical shapes under transmission electron microscopy. The cellular uptake results suggested that FA modification could enhance the cellular internalization of nanoparticulate systems in non-small cell lung cancer, cervical, and breast cancer cell types. Furthermore, cytotoxicity studies showed the superior efficacy of FA-AQ NPs in different cancer cells such as MDAMB-231 and HeLA. FA-AQ NPs had better anti-tumor abilities demonstrated via 3D spheroid cell culture studies. Therefore, FA-AQ NPs could be a promising drug delivery system for cancer therapy.

show abstract

Section: Resultssupporting

confidence: 92%

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

2023

View full text Add to dashboard Cite

show abstract

“…It helps to reduce the epidermal growth factor-induced markers as well as restoration of cell-cell junctions [1,7]. LT-loaded nanoformulations such as folacin-modified nanoparticle [8], nanoparticles [9,10], NLCs [11], folic acid-modified ROS-responsive nanoparticles [12], and nanospheres [13] have been prepared and enhanced bioavailability and efficacy have been reported. However, the application of LT vesicles in the skin cancer has not been reported.…”

Section: Introductionmentioning

confidence: 99%

Formulation, Optimization and Evaluation of Luteolin-Loaded Topical Nanoparticulate Delivery System for the Skin Cancer

et al. 2021

View full text Add to dashboard Cite

In the present study, luteolin (LT)-loaded nanosized vesicles (LT-NVs) were prepared by a solvent evaporation–hydration method using phospholipid and edge activator. The formulation was optimized using three factors at a three-level Box–Behnken design. The formulated LT-NVs were prepared using the three independent variables phospholipid (A), edge activator (B) and sonication time (C). The effect of used variables was assessed on the vesicle size (Y1) and encapsulation efficiency (Y2). The selection of optimum composition (LT-NVopt) was based on the point prediction method of the software. The prepared LT-NVopt showed the particle size of 189.92 ± 3.25 nm with an encapsulation efficiency of 92.43 ± 4.12% with PDI and zeta potential value of 0.32 and −21 mV, respectively. The formulation LT-NVopt was further converted into Carbopol 934 gel (1% w/v) to enhance skin retention. LT-NVoptG was further characterized for viscosity, spreadability, drug content, drug release, drug permeation and antioxidant, antimicrobial and cytotoxicity assessment. The evaluation result revealed optimum pH, viscosity, spreadability and good drug content. There was enhanced LT release (60.81 ± 2.87%), as well as LT permeation (128.21 ± 3.56 µg/cm2/h), which was found in comparison to the pure LT. The antioxidant and antimicrobial study results revealed significantly (p ˂ 0.05) better antioxidant potential and antimicrobial activity against the tested organisms. Finally, the samples were evaluated for cytotoxicity assessment using skin cancer cell line and results revealed a significant difference in the viability % at the tested concentration. LT-NVoptG showed a significantly lower IC50 value than the pure LT. From the study, it can be concluded that the prepared LT-NVoptG was found to be an alternative to the synthetic drug as well as conventional delivery systems.

show abstract

“…Our previous work reported a self-assembly strategy to produce Oxi-αCD NPs (ROS-responsive drug carriers), which exhibited good biocompatibility and could be used as excellent drug delivery carriers ( Zhang et al, 2015 ; Wang et al, 2019 ; Ni et al, 2020 , Wang et al, 2021c .). Briefly, lecithin and DSPE-PEG 2000 were dispersed in anhydrous ethanol and ultrapure water.…”

Section: Methodsmentioning

confidence: 99%

In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis

Yang

Song

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Chronic bacterial prostatitis usually occurs in men and seriously affects the quality of life of patients. The efficacy of chronic bacterial prostatitis treatment is limited by the difficulty for free drugs (e.g., antibiotics) to penetrate the prostate epithelium and target inflammatory tissues. The advent of nanotechnology offers the possibility to address this issue, such as the development of targeted nanoparticle delivery strategies that may overcome these important limitations. The physicochemical properties of nanoparticles, such as particle size, shape and surface modification ligands, determine their targeting effectiveness. In this study, nanoparticles with different physicochemical properties were prepared to explore and confirm their targeting capacities to inflammatory prostate tissues of chronic bacterial prostatitis, focusing on the effects of size and different modification ligands on the targeting performance. In vivo and ex vivo imaging results verified that folic acid-modified nanoparticles with a particle size of 180–190 nm via tail intravenous injection had the optimal targeting efficiency to prostate tissues. Our results provide an experimental basis and reference value for targeted therapy of prostate-related diseases with nanotechnology in the future.

show abstract

Folic acid-modified ROS-responsive nanoparticles encapsulating luteolin for targeted breast cancer treatment

Cited by 26 publications

References 40 publications

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

Development and Characterization of Folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in Cancer Treatment

Formulation, Optimization and Evaluation of Luteolin-Loaded Topical Nanoparticulate Delivery System for the Skin Cancer

In vivo targeting capacities of different nanoparticles to prostate tissues based on a mouse model of chronic bacterial prostatitis

Contact Info

Product

Resources

About